From May 19 to 22, EuroPCR 2026, one of the world’s most influential annual events in interventional cardiology, was grandly held in Paris, France. As a premier global platform for cutting-edge cardiovascular intervention technologies, the congress brought together leading experts, industry professionals, and medical enterprises from around the world to explore new technologies, innovative solutions, and future trends in cardiovascular intervention.
With years of deep expertise in the vascular intervention field, Kossel Medtech showcased its full portfolio of core products spanning peripheral intervention, coronary intervention, and electrophysiology, comprehensively demonstrating the company’s technological expertise and innovation capabilities in precision vascular intervention diagnosis and treatment.
Driven by continuous technological innovation and stringent quality management, multiple core products of Kossel Medtech have successfully obtained MDR CE certification, enabling smooth access to the European market. This achievement has established a solid qualification foundation and strengthened the company’s position for further expansion into Europe, the Middle East, Africa, South America, and other key overseas markets.
Participation in EuroPCR 2026 marked another significant milestone in Kossel Medtech’s global expansion strategy. Throughout the exhibition, the team maintained a professional and open approach, engaging in in-depth discussions with global partners. Through face-to-face communication on product advantages, technical highlights, and regional market support policies, overseas customers gained a comprehensive understanding of Kossel Medtech’s product portfolio, technological strength, and global service capabilities.
The booth attracted strong interest and lively engagement, drawing experienced physicians and distribution partners from dozens of countries, including the United Kingdom, Germany, Austria, Greece, the Netherlands, Belgium, Egypt, Algeria, Jordan, and Argentina. Both parties conducted extensive discussions on key topics such as clinical applications, technology upgrades, regional cooperation, and joint market development, laying a solid foundation for future overseas market expansion and deeper brand establishment.
EuroPCR 2026 served as a concentrated showcase of Kossel Medtech’s product strength and innovation capabilities. Looking ahead, Kossel Medtech will continue to focus on the vascular intervention field, uphold its commitment to technological innovation, and leverage its comprehensive product portfolio and global service network to further expand international markets. By actively building bridges for global cooperation, Kossel Medtech aims to empower clinical practice worldwide with high-quality Chinese medical products and solutions, contributing to the high-quality development of the global vascular intervention industry.